Emerging cardiovascular toxicity associated with CDK4/6 inhibitors: real-world insights from the FDA adverse event reporting system
CVAEs might occur with a greater frequency in the context of CDK4/6i than had been previously acknowledged. Our study provide an overview of the incidence, characteristics and risk factors of CDK4/6i-related CVAEs, and also uncovered potential CVAEs that were not identified in the clinical trials.
Authors
- Wensheng Liu
- Jiyong Liu (ORCID: https://orcid.org/0000-0003-0444-957X)
- Feifei Gao (ORCID: https://orcid.org/0000-0001-8896-352X)
- Youjun She
- Hao Chen (ORCID: https://orcid.org/0000-0003-4339-3441)
- Qiong Du (ORCID: https://orcid.org/0000-0003-4830-9704)
- Xue Song (ORCID: https://orcid.org/0000-0002-9305-9161)
Institutions
- Shanghai Medical College of Fudan University (CN)
- Shanghai Jiao Tong University (CN)
- Renji Hospital (CN)
- Fudan University Shanghai Cancer Center (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-05-30
- DOI
- https://doi.org/10.3389/fphar.2025.1558128
- Citations
- 3
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 4.56